Recently, Hadjipanayis et al reported IONPs (10 nm in core size) conjugated to a purified antibody that selectively binds to the epidermal growth factor receptor (EGFR) deletion mutant (EGFRvIII) present on human glioblastoma multiforme (GBM) cells and used for therapeutic targeting and MRI contrast enhancement of experimental glioblastoma, after convection-enhanced delivery. The gene discussed is EGFR; the disease is glioblastoma.